Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Markets recover early morning losses
Thu, 23 Jun 11:30 am

Indian stock market indices have recovered from morning losses and are now trading in the green. Oil and gas and IT stocks are trading firm, while a FMCG and healthcare stocks are the least gainers.

The BSE-Sensex is up by 76 points while NSE-Nifty is trading 15 points above yesterday's closing. BSE Midcap and BSE Small cap indices are down by 0.5% each. The rupee is trading at 44.91 to the US dollar.

Energy stocks are trading firm led by Reliance Industries and IOC. As per a leading daily, RIL has made another natural gas discovery in the D-9 block of the hydrocarbon rich Krishna Godavari (KG) basin. The block is estimated to have 5.2 10 trillion cubic feet (tcf). As per earlier estimates, the block was expected to hold over 10 tcf of gas reserves. However, this estimate was under revised last year when the first well drilled turned dry in the block. It may be noted that RIL's greatest find in KG basin so far D-6 block has reserves of 11.3 tcf. Investments of US$ 9 bn have been used to develop it. RIL's minority partner Hardy Oil announced this discovery to the London Stock Exchange.

Pharma stocks are trading weak led by Orchid Chemicals and Strides Arcolab. As per a leading financial daily, China is set to open up its US$ 50 bn pharmaceutical market. The Chinese government has a target of bringing almost the entire population within the healthcare insurance framework by 2020. This is going to provide a huge opportunity for Indian pharma companies. This is because they are an ideal choice for sourcing cheap generic medicines. With US$ 70 bn worth of drugs expected to go off patent in the US in the next few years, Indian pharma companies are in a position to play an important role in the resulting new generics markets. With expectations of higher exports to the country in the coming years, Indian pharma companies have already set up offices in China. It may be noted that India's overall pharmaceutical exports touched US$ 12 bn last year and are expected to reach US$ 20 bn by 2015.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets recover early morning losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.